Market News
- Parenteral Solutions in Contract Manufacturing for the Pharmaceutical Industry by Adam Williams (Pharmaceutical Technology) on October 15, 2024
Discover what industry professionals seek in contract manufacturing for parenteral solutions. Download the free Buyer’s Guide today.
- The growing role of CDMOs in the circular economyby Nikki Thompson (Pharmaceutical Technology) on October 15, 2024
Pharmaceutical giants cannot work in a silo to reach net zero. Pharma contract manufactures have a duty to engage with the science-based climate targets, says ACG.
- Oral Solid Dosage Manufacturing Companies, Equipment and Marketby Elli Karampela (Pharmaceutical Technology) on October 15, 2024
Discover key insights into the selection of oral solid dosage manufacturing companies and equipment. Download the free Buyer’s Guide today.
- Boehringer partners WHO Foundation to advance healthcare accessby gullapalli (Pharmaceutical Technology) on October 15, 2024
Boehringer Ingelheim, in partnership with the WHO Foundation, has committed $5m to enhance healthcare access.
- Samsung Biologics Launches High Concentration Platformby OncLive articles on October 15, 2024
S-HiCon can reportedly achieve stable liquid formulation for over 200 mg/mL subcutaneous administration.
- Balancing Personalized Marketing and Maintaining Data Privacyby OncLive articles on October 15, 2024
In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how pharmaceutical companies can effectively balance personalized marketing efforts with […]
- EvolutionIQ Expands AI-Powered Claims Techby OncLive articles on October 15, 2024
MedHub has been expanded to work with a wider variety of insurance plans.
- FDA Approves Single-Dose Regimen of UCB’s Bimzelx for Moderate-to-Severe Plaque Psoriasis, Active Psoriatic Arthritisby OncLive articles on October 15, 2024
Expanded indication of Bimzelx offers a prefilled syringe with a single 2 mL subcutaneous injection, improving upon the previous regimen of two 1 mL injections.
- Pharma Pulse 10/15/24: Understanding Acceptability of eConsent, Advances in Oncology Care & moreby OncLive articles on October 15, 2024
The latest news for pharma industry insiders.
- Lundbeck to acquire Longboard Pharmaceuticals for $2.6bnby gullapalli (Pharmaceutical Technology) on October 15, 2024
Lundbeck is to acquire Longboard for $2.6bn equity value in a move set to enhance its capabilities within neuro-rare conditions.
- ‘Selling a Vision’: Today’s Playbook for Startupsby OncLive articles on October 14, 2024
The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
- Rafaat Rahmani: Beating the Oddsby OncLive articles on October 14, 2024
Rafaat Rahmani, president and founder of Lifescience Dynamics, grew up in abject poverty, but such hardships—and a later violent brush with racism—would ultimately end up fueling a determined and entrepreneurial path in the life sciences.
- Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial by Jenna Philpott (Pharmaceutical Technology) on October 14, 2024
Data from the Rainbowfish trial was presented at the World Muscle Society (WMS) Congress 2024 in Prague, Czech Republic.
- FDA, facing pressure, to review position on Zepbound, Mounjaro shortageby Jonathan Gardner (BioPharma Dive – Latest News) on October 14, 2024
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in supply.
- Lundbeck to buy brain drug developer Longboard for $2.6Bby Jacob Bell (BioPharma Dive – Latest News) on October 14, 2024
The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company’s estimates, become a blockbuster product.
- GSK says antibody drug succeeds in testing for chronic nasal conditionby Delilah Alvarado (BioPharma Dive – Latest News) on October 14, 2024
The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.
- Pfizer drug for hemophilia approved by FDAby Ned Pagliarulo (BioPharma Dive – Latest News) on October 14, 2024
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
- Lundbeck Agrees to Terms to Acquire Longboard Pharmaceuticalsby OncLive articles on October 14, 2024
Acquisition of Longboard grants Lundbeck access to bexicaserin, 5-HT2C receptor agonist that has demonstrated promise in treating seizures associated with rare developmental epileptic encephalopathies.
- Leading Cybersecurity Companies for the Pharmaceutical Industryby timthomas (Pharmaceutical Technology) on October 14, 2024
Discover the leading Cybersecurity Companies for the Pharmaceutical Industry. Download the free Buyer’s Guide today for full contact details.
- FDA Approves Pfizer’s Hympavzi for Prophylaxis in Patients with Hemophilia A or Bby OncLive articles on October 14, 2024
Hympavzi is the first anti-tissue factor pathway inhibitor therapy to be approved in the United States for routine prophylaxis of bleeding in patients with hemophilia A or B without inhibitors.